CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 298 enrolled
Drug / intervention
Belimumabbiological
Likely dose
Belimumab 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00583362
NCT00583362Phase 2Completed
CompareCT.gov

A Multi-Center, Open-Label, Continuation Trial LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 2 Protocol LBSL02

Human Genome Sciences Inc., a GSK Company·interventional·Posted Dec 31, 2007·Updated Jul 23, 2019

In Brief

A Phase 2 clinical trial evaluating Belimumab for Systemic Lupus Erythematosus. Completed, enrolled 298 participants across 57 sites in 2 countries.

Detailed Summary

This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesCanada, United States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 31, 2007
Enrollment StartMay 4, 2005
Primary CompletionFeb 23, 2016
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 18.5 years ago

Interventions

Belimumabbiological

Belimumab 10mg/kg IV over one hour every 28 days